Oncternal Therapeutics Inc
$ 0.53
0.00%
17 Apr - close price
- Market Cap 1,558,500 USD
- Current Price $ 0.53
- High / Low $ 0.53 / 0.53
- Stock P/E N/A
- Book Value 3.09
- EPS -11.69
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -1.50 %
- 52 Week High 0.53
- 52 Week Low 0.53
About
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, California.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-04 | 2023-03-09 | 2022-11-03 | 2022-08-09 | 2022-05-05 | 2022-03-10 |
| Reported EPS | -2.86 | -2.89 | -2.83 | -3.11 | -0.17 | -0.15 | -0.2 | -0.2 | -0.21 | -0.23 | -0.2 | -0.16 |
| Estimated EPS | -3.19 | -3.1 | -2.88 | -3.07 | -0.14 | -0.16 | -0.2 | -0.21 | -0.24 | -0.23 | -0.2 | -0.25 |
| Surprise | 0.33 | 0.21 | 0.05 | -0.04 | -0.03 | 0.01 | 0 | 0.01 | 0.03 | 0 | 0 | 0.09 |
| Surprise Percentage | 10.3448% | 6.7742% | 1.7361% | -1.3029% | -21.4286% | 6.25% | 0% | 4.7619% | 12.5% | 0% | 0% | 36% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ONCT
2025-12-13 12:09:25
Oncternal Therapeutics (NASDAQ: ONCT) is a clinical-stage biopharmaceutical company focused on developing oncology therapies. The company's pipeline includes zilovertamab, ONCT-216, ONCT-808, and ONCT-534, all aimed at various cancers. Recent news indicates the company is winding down operations and voluntarily delisting from Nasdaq.
2025-04-25 16:11:14
Oncternal Therapeutics, Inc. (ONCT) is a clinical-stage biopharmaceutical company focused on oncology therapies. However, recent press releases indicate a significant shift, with the company discontinuing clinical trials for ONCT-534 and ONCT-808, selling its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc., and initiating a wind-down of its operations. Investors are advised to consider that ONCT now represents a company in the process of winding down rather than an active drug development entity.
2025-03-08 05:05:00
Oncternal Therapeutics (Nasdaq: ONCT) announced its intention to voluntarily delist its securities from Nasdaq and subsequently deregister with the SEC. The company will file a Form 25 on March 17, 2025, and then a Form 15 ten days after the Nasdaq delisting becomes effective, which will suspend its obligation to file periodic reports with the SEC. This action follows Nasdaq's suspension of trading of Oncternal's common stock on December 3, 2024.
2025-03-07 03:52:10
Oncternal Therapeutics announced its intention to voluntarily delist its securities from Nasdaq and subsequently deregister with the SEC. The company plans to file a Form 25 on March 17, 2025, which will be followed by a Form 15 filing ten days after Nasdaq delisting becomes effective, suspending its obligation to file periodic reports. Nasdaq had previously suspended trading of Oncternal's stock and notified the company of its intention to file a Form 25, but Oncternal is proceeding voluntarily.
2024-08-08 11:11:03
Oncternal Therapeutics (Nasdaq: ONCT) announced its second-quarter 2024 financial results and provided a business update. Key highlights include the progression of its Phase 1/2 studies for ONCT-534 (advanced prostate cancer) and ONCT-808 (aggressive B-cell lymphoma), with initial ONCT-534 data expected in Q3 2024 and further updates in Q4 2024. The company reported $21.4 million in cash, cash equivalents, and short-term investments as of June 30, 2024, projecting a cash runway into Q1 2025, alongside a net loss of $8.6 million for Q2 2024.
2024-01-04 06:51:34
Oncternal Therapeutics (NASDAQ: ONCT) announced a 1-for-20 reverse stock split of its common stock, effective January 8, 2024, to comply with Nasdaq's minimum bid price requirement. This adjustment will convert every 20 shares into one, with proportional changes to outstanding options and warrants, and cash payments for fractional shares. The company aims for its stock to trade above $1.00 for ten consecutive business days to regain compliance.
